Following People With COPD Who Still Feel Short of Breath
Follows adults with COPD whose breathlessness continues despite regular inhaler treatment.
Plain-language title generated from the registry record
Registry title: Refractory Breathlessness in COPD
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07160322, who can take part
Where in South Korea
- Seoul National University College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University
- Trial code
- NCT07160322
- Record updated
- 8 September 2025
- Original description
This study aims to investigate the prognosis and clinical outcomes of patients with chronic obstructive pulmonary disease (COPD) who continue to experience refractory dyspnea despite treatment with long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA). The research will prospectively follow a cohort of patients to identify clinical factors, lung function parameters, imaging features, and cardiovascular indicators associated with poor treatment response. By comparing these patients with those who show symptom improvement, the study seeks to determine predictors of exacerbations, lung function decline, and mortality. Findings are expected to guide the development of targeted strategies to improve the management of refractory dyspnea in COPD.Read full original descriptionShow less
Prognosis and Clinical Outcomes of Refractory Dyspnea in Chronic Obstructive Pulmonary Disease: Prospective Observational Study
This study aims to investigate the prognosis and clinical outcomes of patients with chronic obstructive pulmonary disease (COPD) who continue to experience refractory dyspnea despite treatment with long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA). The research will prospectively follow a cohort of patients to identify clinical factors, lung function parameters, imaging features, and cardiovascular indicators associated with poor treatment response. By comparing these patients with those who show symptom improvement, the study seeks to determine predictors of exacerbations, lung function decline, and mortality. Findings are expected to guide the development of targeted strategies to improve the management of refractory dyspnea in COPD.
Inclusion: Adults (≥ 18 years) diagnosed with chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 criteria:; Presence of COPD risk factors (e.g., smoking history, occupational exposure, genetic predisposition); Typical symptoms such as dyspnea, cough, or sputum production; Post-bronchodilator FEV1/FVC < 0.70; Regular outpatient follow-up at the respiratory clinic; Received LABA/LAMA combination therapy for at least 3 months prior to enrollment; Ability and willingness to provide written informed consent.
Exclusion: Poor adherence to LABA/LAMA therapy (medication possession rate < 50%) or refusal of treatment; Presence of severe comorbid conditions expected to significantly affect prognosis, including:; End-stage diseases with life expectancy < 1 year; Terminal malignancies receiving hospice or palliative care; Any condition that, in the opinion of the investigator, would interfere with study participation or data reliability; Inability or unwillingness to comply with scheduled visits, examinations, or follow-up procedures.